CNS relapse of B-lymphoblastic lymphoma after allogeneic  hematopoietic stem cell transplantation: therapy with donor  CD19-specific CAR-T cells

O. O. Molostova; Молостова О. О.; L. N. Shelikhova; Шелихова Л. Н.; D. E. Pershin; Першин Д. Е.; A. M. Popov; Попов А. М.; M. E. Dubrovina; Дубровина М. Э.; M. A. Klimentova; Климентова М. А.; A. A. Maschan; Масчан А. А.; M. A. Maschan; Масчан М. А.

doi:10.24287/1726-1708-2021-20-2-143-147

CNS relapse of B-lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation: therapy with donor CD19-specific CAR-T cells

Authors: Molostova O.O.¹, Shelikhova L.N.¹, Pershin D.E.¹, Popov A.M.¹, Dubrovina M.E.¹, Klimentova M.A.¹, Maschan A.A.¹, Maschan M.A.¹
Affiliations:
1. Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Issue: Vol 20, No 2 (2021)
Pages: 143-147
Section: CLINICAL OBSERVATIONS
Submitted: 22.05.2021
Accepted: 22.05.2021
Published: 22.05.2021
URL: https://hemoncim.com/jour/article/view/517
DOI: https://doi.org/10.24287/1726-1708-2021-20-2-143-147
ID: 517

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Presently, there is no consensus on the best treatment for relapsed B-cell acute lymphoblastic leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation (allo-HSCT), particularly in patients with extramedullary lesions. There are certain anti-tumor drugs that can be used in case of relapse after allo-HSCT, however, prospective randomized studies directly comparing different chemotherapy and immunotherapy approaches are generally lacking. Retrospective studies exploring therapy for relapsed disease are difficult to compare due to the inhomogeneity of patient populations and the diversity of treatment approaches. In such situations, the treatment choice is influenced by the characteristics of the tumor population, particularly, its immunophenotype, available drugs, and the experience of a healthcare facility and physicians. This clinical case report describes the process of treating a patient with B-lymphoblastic lymphoma and shows the possibility of using donor CD19-specific CAR-T cells as a treatment for isolated CNS relapse after allo-HSCT. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications.